San Diego – May 10, 2017 – Cooley advised Horizon Pharma on its acquisition of River Vision and its development-stage eye medicine teprotumumab for approximately $145 million plus potential future milestone and earn-out payments.
“This acquisition is an important step in our strategy of pursuing and acquiring development-stage medicines targeting rare diseases,” said Timothy P. Walbert, Horizon’s chairman, president and CEO, in a news release. “With no approved medicines to treat thyroid eye disease, there is a significant unmet treatment need among the approximately 10,000 patients in the United States with moderate to severe disease and we look forward to beginning the pivotal study with teprotumumab in the second half of this year.”
Horizon, headquartered in Dublin, Ireland, is a specialty biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated products that address unmet medical needs. The company markets a portfolio of products in arthritis, inflammation and orphan diseases.
Cooley helped take Horizon public in 2011 and has represented Horizon on nine publicly announced acquisitions and numerous credit, debt and equity financings, including its largest acquisition to date – the acquisition of Hyperion Therapeutics for $1.1 billion. In 2016, Cooley advised the company on its $800 million acquisition of Raptor Pharmaceutical.
About Cooley LLP
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law.
Cooley has 900 lawyers across 12 offices in the United States, China and Europe.